Damora Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-209.8M | $-21.4M | $-38.3M | $-61.6M | $-51.8M | $-34.8M | $-36.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $22.0K | $21.0K | $269.0K | $42.0K | $20.0K | — | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $998.0K | $3.2M | $5.4M | $5.6M | $4.5M | $982.0K | — |
| Net Cash from Operating Activities | $-6.7M | $-18.6M | $-36.9M | $-42.9M | $-52.3M | $-38.2M | $-19.3M |
| Investing Activities | |||||||
| Capital Expenditures | — | — | — | $196.0K | $223.0K | — | — |
| Business Acquisitions | $17.4M | — | — | — | — | — | $326.0K |
| Net Cash from Investing Activities | $-17.4M | $11.7M | $22.3M | $12.4M | $-48.0M | — | $-326.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $266.8M | — | $2.9M | $507.0K | — | $187.4M | — |
| Net Change in Cash | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | $-43.1M | $-52.5M | — | — |